Mariner’s Protara Therapeutics TARA Stock Holding History

Mariner’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-250	Closed	-$5K	–	1148
2019 Q1	$5K	Hold	250	–	–	﹤0.01%	1028
2018 Q4	$23K	Hold	250	–	–	﹤0.01%	828
2018 Q3	$20K	Hold	250	–	–	﹤0.01%	804
2018 Q2	$25K	Hold	250	–	–	﹤0.01%	782
2018 Q1	$25K	Hold	250	–	–	﹤0.01%	633
2017 Q4	$19K	Hold	250	–	–	﹤0.01%	575
2017 Q3	$20K	Hold	250	–	–	﹤0.01%	502
2017 Q2	$15K	Sell	250 -28	-10%	-$1.57K	﹤0.01%	498
2017 Q1	$19K	Hold	278	–	–	﹤0.01%	585
2016 Q4	$21K	Buy	+278	New	+$87.9K	﹤0.01%	557

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Mariner's TARA Position: Q2 2019 in Review

Mariner sold out of Protara Therapeutics (TARA) in Q2 2019, closing a stake of 250 shares — an estimated $5K sold.

Mariner first reported a position in TARA in Q4 2016 and held it in 10 quarters. The position peaked at $25K in Q2 2018. 15 funds tracked by Wall St. Rank hold TARA as of Q2 2019.

Mariner reported no remaining Protara Therapeutics position as of Q2 2019 after selling out during the quarter.
Mariner sold 250 Protara Therapeutics shares in Q2 2019, an estimated $5K.
Mariner first reported a position in Protara Therapeutics in Q4 2016 and held it in 10 quarters.
Mariner's Protara Therapeutics position peaked at $25K in Q2 2018.
15 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2019.

Based on Mariner's 13F filing for Q2 2019, filed 14 Aug 2019.